Trump signs executive actions to boost domestic drug manufacturing and tighten oversight on gain-of-function research, raising concerns over potential higher costs and shortages.
Rite Aid files for second bankruptcy in less than a year, citing vendor restrictions and lack of lender support as key reasons.
Trump signs executive actions to boost domestic drug manufacturing and tighten oversight on gain-of-function research, raising concerns over potential higher costs and shortages.
Rite Aid files for second bankruptcy in less than a year, citing vendor restrictions and lack of lender support as key reasons.